文献速递消化系统肿瘤妇科肿瘤

结直肠癌与子宫内膜癌MSI/IHC检测及PREMM5风险评分对多基因面板检测致病胚系变异的预测比较

Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.
PubMed 文献 · J Clin Oncol · 2020-09-30

该研究回顾性分析两个单中心队列(高危队列706例,肿瘤门诊队列1058例),比较MSI/IHC与PREMM5模型识别Lynch综合征(LS)及非LS致病胚系变异(PV)的能力。结果显示两者对LS敏感性相当,但MSI/IHC特异性更优;PREMM5对非LS高外显率PV敏感性更优,在MSI/IHC正常者中仍可识别多数高外显率PV携带者。

要点

  • MSI/IHC与PREMM5对LS识别敏感性相当,但MSI/IHC特异性显著更高。
  • PREMM5对非LS高外显率PV的敏感性优于MSI/IHC。
  • MSI/IHC正常但PREMM5≥2.5%者仍应接受多基因面板检测。

核心结论

  • MSI/IHC和PREMM5均能有效识别结直肠癌和/或子宫内膜癌患者的LS,但MSI/IHC对LS特异性更好。
  • PREMM5可识别非LS高外显率胚系PV,PREMM5评分≥2.5%者(包括MSI/IHC正常者)应提供多基因面板检测。

研究设计与样本

  • 回顾性分析两个单中心队列:高危队列706例因遗传评估/检测转诊的结直肠癌和/或子宫内膜癌患者。
  • 肿瘤门诊队列1058例连续确诊的结直肠癌患者,未根据家族风险选择。
  • 所有参与者均接受胚系多基因面板检测,PREMM5评分根据个人/家族癌症史计算。

主要发现

  • 在肿瘤门诊队列中,MSI/IHC与PREMM5对LS携带者的敏感性均为96.6%(P=1.000)。
  • 在两个队列中,PREMM5对任何高外显率PV及任何低、中、高外显率PV的敏感性均优于MSI/IHC。

关键数值与推荐

  • PREMM5评分≥2.5%被用作阳性阈值。

临床怎么用

  • 对结直肠癌和/或子宫内膜癌患者,MSI/IHC可用于LS筛查,但特异性有限。
  • PREMM5评分≥2.5%应视为多基因面板检测的指征,即使MSI/IHC正常。
  • 临床应结合MSI/IHC和PREMM5以提高LS及非LS遗传性癌症综合征的检出。

局限性

  • 回顾性研究设计。
  • 两个单中心队列,可能存在选择偏倚。
  • 结果需在外部队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor testing for microsatellite instability and/or mismatch repair-deficiency (MSI/IHC) and clinical prediction models effectively screen for Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer (EC), but they have not been assessed for their ability to identify non-LS forms of inherited risk. The aim of this study was to compare MSI/IHC and the PREMM5 prediction model to identify carriers of LS and non-LS pathogenic variants (PVs) among patients with CRC and EC. PATIENTS AND METHODS: Data were retrospectively analyzed from two single-institution cohorts: 706 patients with CRC and/or EC referred for genetic evaluation/testing (high-risk cohort) and 1,058 consecutively ascertained patients with CRC (oncology clinic cohort), unselected for familial risk. All participants underwent germline multigene panel testing. PREMM5 scores were calculated from personal/family cancer history. The primary outcome was the proportion of individuals with germline PVs (LS PVs, high-penetrance PVs, and any PVs) who had abnormal MSI/IHC testing and/or PREMM5 score ≥ 2.5%. RESULTS: MSI/IHC and PREMM5 had comparable sensitivity for identifying LS carriers in high-risk (89.3% v 85.7%; P = .712) and oncology clinic patients (96.6% v 96.6%; P = 1.000), although MSI/IHC had significantly superior specificity for LS (81.3% v 20.1%; P < .001; 92.3% v 24.3%; P < .001). In both cohorts, PREMM5 had superior sensitivity to MSI/IHC at identifying patients with any high-penetrance PVs and any low-, moderate-, and high-penetrance PVs. Among patients with normal MSI/IHC, PREMM5 identified 84.2% and 83.3% of high-risk patients with CRC/EC and oncology clinic CRC patients with high-penetrance PVs, respectively. CONCLUSION: MSI/IHC and PREMM5 effectively identify patients with CRC and/or EC with LS, although MSI/IHC has better specificity for LS. Because PREMM5 identifies non-LS, high-penetrance germline PVs, patients with CRC and/or EC with PREMM5 score ≥ 2.5%, including those with normal MSI/IHC, should be offered multigene panel testing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mannucci A, Furniss CS, Ukaegbu C, et al. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. J Clin Oncol. 2020. PMID: 32997573. doi:10.1200/JCO.20.01470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。